|
|
Office Locations:
|
411 Lafayette St, 6th Floor
New York, NY 10003
| |
|
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
TIO Bioventures is a boutique venture creation firm focused on funding the advancement of biotechnology companies that are guided by its principles of employing research-driven science to create first-in-class cancer medicines. Unlike a traditional venture fund, TIO Bioventures leverages its internal TIO Discovery to provide R&D and management services to its portfolio companies. To date, the majority of financing for TIO Discovery and TIO portfolio company drug discovery and development efforts has come from non-dilutive funds from philanthropic and competitive grant awards, such as those from the Canadian Foundation for Innovation, the collaborative funding partnership between The California Institute for Regenerative Medicine (CIRM) and the Cancer Stem Cell Consortium (CSCC), and the Princess Margaret Hospital (PMH) Foundation. In 2020, the firm will close their first fund, TIO Bioventures Fund I.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
